Nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:Medial Group Retropharyngeal Node Sparing
Active Comparator:Medial Group Retropharyngeal Node with Prophylactic Irradiation
Sponsors
Cancer Center, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients without medial group retropharyngeal node metastasis; 2. Patients with newly histologically confirmed non-keratinizing (according to WHO histologically type); 3. Tumor staged as T1-4N0-3(according to the 8th AJCC edition); 4. No evidence of distant metastasis (M0); 5. Satisfactory performance status: Karnofsky scale (KPS) = 70; 6. Patients must be informed of the investigational nature of this study and give written informed consent.;Inclusion criteria: 1. Patients without medial group retropharyngeal node metastasis; 2. Patients with newly histologically confirmed non-keratinizing (according to WHO histologically type); 3. Tumor staged as T1-4N0-3(according to the 8th AJCC edition); 4. No evidence of distant metastasis (M0); 5. Satisfactory performance status: Karnofsky scale (KPS) = 70; 6. Patients must be informed of the investigational nature of this study and give written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with medial group retropharyngeal node metastasis; 2. Aged > 65 or 65 or < 18; 3. Treatment with palliative intent; 4. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer; 5. Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period); 6. With history of previous RT (except for non-melanomatous skin cancers outside intended RT treatment volume); 7. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes; 8. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local replase-free survival rate;;Local replase-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of acute and late toxicity;Incidence of out-field recurrence rate;Dysphagia related quality of life;Overall survival;;Incidence of acute and late toxicity;Incidence of out-field recurrence rate;Dysphagia related quality of life;Overall survival; | — |
Countries
China
Contacts
Public ContactYanping Mao;Yanping Mao ;
Department of Radiation Oncology, Cancer Center, Sun Yat-Sen University;Department of Radiation Oncology, Cancer Center, Sun Yat-Sen University
Outcome results
None listed